< Previous page ^ Table of Contents Next page >

Graces submitted to the Regent House on 4 February 2009

The Council submits the following Graces to the Regent House. These Graces, other than any which is withdrawn or for which a ballot is requested in accordance with the regulations for Graces of the Regent House (Statutes and Ordinances, p. 107), will be deemed to have been approved at 4 p.m. on Friday, 13 February 2009.

1. That the Council be authorized to approve certain amendments of the Rules of the Contributory Pension Scheme.1

2. That Regulation 2 for the Jawaharlal Nehru Professor of Indian Business and Enterprise be amended by attaching at the end of the regulation the words 'and after consultation with the donor'.2

3. That a Waldmann Fund be established in the University, to be governed by the following regulations:3

Waldmann Fund

1. The sum of £1.2m received by the University, via Cambridge University Technical Services Ltd, in connection with income arising from the commercial exploitation of the antibody CAMPATH 1 shall form a fund entitled the Waldmann Fund. This title recognizes the work of Professor Herman Waldmann (leader of a research group in the Department of Pathology in the University of Cambridge which also included Dr Michael Clark, Dr Geoff Hale, and Dr Stephen Cobbold), in developing CAMPATH 1 for use in therapy of human diseases. The income derived from the Fund shall be used solely for the benefit of the Department of Pathology and its purposes.

2. The Managers of the Fund shall comprise both the Head of the Department of Pathology for the time being and the Professor of Immunology (being the Head of the Division of Immunology) in the Department of Pathology for the time being and three persons appointed by the Faculty Board of Biology in the Michaelmas Term to serve for a period of four years from 1 January following their appointment. In the event of the Head of Department of Pathology or the Professor of Immunology at any stage being unable or unwilling to serve as Managers a replacement shall be appointed by the General Board on the recommendation of the Faculty Board of Biology, to hold office for four years or until such time as the new incumbent is elected to the relevant office.

3. The income of the Fund shall be used as the Managers shall from time to time determine for any one or more of the following purposes, namely:

(i) the support of research studentships within the Department of Pathology;
(ii) the repair and maintenance of existing equipment or purchase of new equipment in the Department; and
(iii) the overall support and enhancement of the quality and breadth of (a) research implemented within the Department including provision of new (and improvement of existing) premises and facilities appropriate for such research; and (b) research initiated or sponsored by the Department.

4. Any unexpended income of the Fund in any financial year may either be added to the capital of the Fund or accumulated for use as income in any one or more subsequent years, as determined by the Managers.

5. The Managers may accept additional sums from time to time for the same purpose and add them to the capital of the Fund.

6. All powers and discretions conferred on the Managers by this Grace, general law, and statute shall be exercised by a decision of a majority consisting of at least three Managers, who shall include the Head of Department of Pathology or the Professor of Immunology, present and voting at any meeting.

4. That the recommendations in paragraph 9 of the Report of the General Board on Diplomas and Certificates awarded by the Institute of Continuing Education and other bodies (Reporter, p. 184) be approved.4

1 See the Council's Notice on p. 466.

2 Statutes and Ordinances, p. 703. The High Commission of India has expressed a desire to be consulted about the use of any excess income in the Jawaharlal Nehru Fund for Indian Business and Enterprise: the proposed amendment to the regulations makes provision for this.

3 The Department of Pathology has received income through Cambridge University Technical Services Ltd in connection with the commercial exploitation of monoclonal antibodies for therapy of human diseases, pioneered by Professor Waldmann and his research group in the University. Regulations to govern the use of this income are now proposed.

4 See the Council's Notice on p. 467.


J. W. NICHOLLS, Registrary


< Previous page ^ Table of Contents Next page >

Cambridge University Reporter 4 February 2009
Copyright © 2011 The Chancellor, Masters and Scholars of the University of Cambridge.